Breaking Boundaries: Alterity Therapeutics to Showcase Groundbreaking Research at the International Congress of Parkinson’s Disease and Movement Disorders
Description:
Late Breaking Abstract and Oral Presentation on ATH434-202 Interim Phase 2 Data
Oral Presentation on ATH434-201 Phase 2 Baseline Characteristics
MELBOURNE, Australia and SAN FRANCISCO, Sept. 23, 2024 (GLOBE NEWSWIRE) — Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that multiple oral and poster presentations will be presented at the International Congress of Parkinson’s Disease and Movement Disorders® (MDS) taking place September 27 – October 1, 2024 in Philadelphia, PA.
Exploring the Future of Neurodegenerative Disease Treatment
Neurodegenerative diseases pose a significant challenge to healthcare providers and researchers around the world. These conditions, including Parkinson’s Disease, Alzheimer’s Disease, and Huntington’s Disease, are characterized by the progressive degeneration of neurons in the central nervous system, leading to a range of debilitating symptoms.
Alterity Therapeutics is at the forefront of developing innovative treatments for these devastating diseases. Their groundbreaking research focuses on targeting the underlying mechanisms of neurodegeneration, with the goal of providing disease-modifying therapies that can slow or halt disease progression.
At the International Congress of Parkinson’s Disease and Movement Disorders, Alterity will be sharing new data from their Phase 2 clinical trials of ATH434-202 and ATH434-201. These presentations will provide valuable insights into the efficacy and safety of these novel compounds, offering hope for patients and caregivers alike.
Impact on Individuals:
For individuals living with neurodegenerative diseases, the research being presented by Alterity Therapeutics has the potential to be life-changing. If successful, these new treatments could slow or stop the progression of their condition, improving quality of life and providing hope for a brighter future.
Impact on the World:
The work being done by Alterity Therapeutics has far-reaching implications for the field of neurodegenerative disease research. By pushing the boundaries of scientific knowledge and innovation, they are paving the way for new treatment options that could benefit millions of people worldwide. This research has the potential to not only improve individual patient outcomes but also to reduce the burden of these diseases on healthcare systems and society as a whole.
Conclusion
Alterity Therapeutics’ participation in the International Congress of Parkinson’s Disease and Movement Disorders represents a significant milestone in the fight against neurodegenerative diseases. Through their commitment to groundbreaking research and innovative therapies, they are breaking boundaries and offering hope to individuals and the world as a whole. The future of neurodegenerative disease treatment is looking brighter thanks to the dedication and expertise of companies like Alterity Therapeutics.
